MX353096B - Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. - Google Patents
Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.Info
- Publication number
- MX353096B MX353096B MX2013001917A MX2013001917A MX353096B MX 353096 B MX353096 B MX 353096B MX 2013001917 A MX2013001917 A MX 2013001917A MX 2013001917 A MX2013001917 A MX 2013001917A MX 353096 B MX353096 B MX 353096B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- mci
- cognitive impairment
- miild
- discorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013001917A MX2013001917A (es) | 2013-10-25 |
| MX353096B true MX353096B (es) | 2017-12-19 |
Family
ID=45605447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001917A MX353096B (es) | 2010-08-19 | 2011-08-19 | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (enExample) |
| EP (1) | EP2605655B1 (enExample) |
| JP (2) | JP6250394B2 (enExample) |
| AU (1) | AU2011291506B2 (enExample) |
| BR (1) | BR112013003847A8 (enExample) |
| CA (1) | CA2808630A1 (enExample) |
| DK (1) | DK2605655T3 (enExample) |
| ES (1) | ES2705027T3 (enExample) |
| MX (1) | MX353096B (enExample) |
| WO (1) | WO2012024616A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| US20150209306A1 (en) | 2012-08-07 | 2015-07-30 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| EP3653609B1 (en) | 2013-02-12 | 2024-04-03 | Buck Institute for Research on Aging | Hydantoins that modulate bace-mediated app processing |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| AU2016220049C1 (en) | 2015-02-18 | 2021-02-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| JP2018516901A (ja) * | 2015-05-18 | 2018-06-28 | シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ | アミロイドβのガランタミンクリアランス |
| EP3347002B1 (en) | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| US10441573B2 (en) | 2015-12-09 | 2019-10-15 | Brandeis University | DBH inhibitors for treating memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| AU2017264931B2 (en) | 2016-05-12 | 2021-02-04 | Buck Institute For Research On Aging | Compounds to promote normal processing of APP |
| JP7790686B2 (ja) | 2017-01-03 | 2025-12-23 | バイオアトラ インコーポレイテッド | 老化細胞の処置のためのタンパク質療法 |
| MX2021000395A (es) | 2018-07-11 | 2021-05-12 | Rubedo Life Sciences Inc | Composiciones senolíticas y usos de las mismas. |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| JP7618230B2 (ja) | 2019-07-25 | 2025-01-21 | 学校法人東京理科大学 | 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| JPH06507782A (ja) | 1990-06-15 | 1994-09-08 | サイオス ノバ インコーポレイテッド | アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物 |
| AU652997B2 (en) | 1991-01-21 | 1994-09-15 | Elan Pharmaceuticals, Inc. | Test and model for alzheimer's disease |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| DE69233109T2 (de) | 1992-01-07 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Transgene tiermodelle fur alzheimer-krankheit |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| ES2318902T3 (es) | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| JP4288263B2 (ja) | 2002-10-25 | 2009-07-01 | コレジウム ファーマシューティカル， インク． | ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法 |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| US7794403B2 (en) | 2004-04-21 | 2010-09-14 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| US8470846B2 (en) * | 2004-04-30 | 2013-06-25 | National University Corporation Chiba University | Remedy for psychoneurotic diseases |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| JP2008524332A (ja) | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
| DE602005019210D1 (de) | 2004-12-23 | 2010-03-18 | Xenoport Inc | Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon |
| US20090156581A1 (en) | 2005-04-15 | 2009-06-18 | Board Of Trustrees Of Michigan State University | Aminergic pharmaceutical compositions and methods |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1993542A1 (en) | 2006-03-01 | 2008-11-26 | Galderma Research & Development, S.N.C. | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| SG173409A1 (en) | 2006-11-24 | 2011-08-29 | Ac Immune Sa | N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| CN101742991A (zh) | 2007-05-03 | 2010-06-16 | 杰克·L·阿比瑟 | 和厚朴酚类似物及其在治疗癌症中的用途 |
| US20090163451A1 (en) | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| US20110118189A1 (en) | 2008-04-28 | 2011-05-19 | Farr Stephen J | Novel formulations for treatment of migraine |
| KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
| US8604087B2 (en) | 2008-09-25 | 2013-12-10 | Bioland Ltd. | Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol |
| BRPI0914080A2 (pt) | 2008-10-08 | 2015-10-27 | Bioplus Life Sciences Pvt Ltda | "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo" |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| US9017718B2 (en) | 2009-05-21 | 2015-04-28 | Bionex Pharmaceuticals Llc | Dual and single layer dosage forms |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US20150030683A1 (en) | 2012-02-18 | 2015-01-29 | Buck Institute For Research On Aging | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
-
2011
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6250394B2 (ja) | 2017-12-20 |
| US10449177B2 (en) | 2019-10-22 |
| BR112013003847A8 (pt) | 2017-12-26 |
| EP2605655B1 (en) | 2018-10-24 |
| EP2605655A1 (en) | 2013-06-26 |
| BR112013003847A2 (pt) | 2016-05-31 |
| AU2011291506A1 (en) | 2013-03-14 |
| CA2808630A1 (en) | 2012-02-23 |
| DK2605655T3 (en) | 2019-02-04 |
| JP2016193944A (ja) | 2016-11-17 |
| AU2011291506B2 (en) | 2016-07-28 |
| EP2605655A4 (en) | 2014-01-08 |
| MX2013001917A (es) | 2013-10-25 |
| US20120071468A1 (en) | 2012-03-22 |
| ES2705027T3 (es) | 2019-03-21 |
| JP2013534256A (ja) | 2013-09-02 |
| WO2012024616A1 (en) | 2012-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| BR112013003847A2 (pt) | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| CY1118542T1 (el) | Φθορομεθυλ-υποκατεστημενα καρβοξαμιδια πυρρολιου | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |